

# At cancer diagnosis A window of opportunity for behavioural change towards physical activity for colon and breast cancer patients

<b>Submission date</b> 25/01/2012	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 04/04/2012	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 17/12/2020	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Survival following colon or breast cancer is now possible for 50 to 80% of patients who receive chemotherapy. Studies have found that increased physical activity and regular exercise have favorable physical, functional and emotional effects during chemotherapy. Furthermore, sustained exercise of moderate to high intensity may improve long-term survival. The aim of this study is to investigate whether it is possible to support and motivate previously inactive patients to initiate and maintain physical activity during and after their chemotherapy treatment and to increase their physical fitness.

### Who can participate?

Sedentary (inactive) patients with colon or breast cancer receiving chemotherapy.

### What does the study involve?

This study tests the feasibility and effectiveness of two 12-week programs of varying intensity and exercise setting. All participants receive the oncologist's advice to meet national recommendations for physical activity. Participants are randomly assigned to one of three groups. The first group receives a supervised 12-week hospital-based moderate-to-high intensity physical training program. The second group receives a non-supervised 12-week home-based program with a view to increasing their physical activity to the minimum national recommendations of 150 minutes of moderate activity plus at least two times 20 minutes of strenuous activity per week. The third group are offered one of the two exercise programs after the 12-week period.

### What are the possible benefits and risks of participating?

Not provided at time of registration.

### Where is the study run from?

The hospital exercise facilities are located at the Copenhagen University Hospital Rigshospitalet and are a part of Center for Integrated Rehabilitation (CIRE) affiliated to Copenhagen University, Faculty of Health Sciences.

When is the study starting and how long is it expected to run for?  
January 2012 to January 2013.

Who is funding the study?  
Novo Nordic Foundation and the Danish Cancer Society.

Who is the main contact?  
Tom Møller  
tom@ucsf.dk

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Mr Tom Møller

**Contact details**  
Copenhagen University Hospital Rigshospitalet Department 9701  
Blegdamsvej 9  
Copenhagen  
Denmark  
2100  
+45 (0)3545 7366  
tom@ucsf.dk

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
N/A

## Study information

**Scientific Title**  
At cancer diagnosis A window of opportunity for behavioural change towards physical activity for colon and breast cancer patients: a randomised feasibility study

**Study objectives**  
The overall hypothesis is that intervention initiated early in the treatment of (pre-diagnostic) non-workout accustomed patients with breast and colon cancer will increase the aerobic capacity, physical activity, improve patients reaction control and functional, emotional and social capacity and reduce the risk of lifestyle comorbidity.

A supervised hospital-based multidimensional intervention compared with an unsupervised home pedometer-based intervention after 12 weeks will be more effective in relation to:

1. Increase the maximal oxygen uptake (VO<sub>2</sub>-peak) and muscle strength (1 RM)
2. To motivate patients to improve and maintain their physical activity level of 150 min /week and at least 20 minutes strenuous exercise twice weekly
3. To improve vitality, functional capacity, general well being, pain, sleep problems, fatigue and depression
4. To promote health behaviour (smoking), social integration and return to work

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

1. Ethical Committee of the Capital Region Copenhagen Denmark, 19/12/2011, ref: H-1-2011-131
2. The Danish Data Protection Agency, ref: J.nr. 2011-41-6349

### **Study design**

Three-armed randomised feasibility study

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Hospital

### **Study type(s)**

Treatment

### **Participant information sheet**

Not available in web format, please use the contact details below to request a patient information sheet

### **Health condition(s) or problem(s) studied**

Colon and breast cancers receiving adjuvant chemotherapy

### **Interventions**

Two interventions are tested with a comparable control group. All study group participants receives the oncologists advice of meeting national recommendations for physical activity. The two intervention groups receives motivational and individual counseling to support behavioural change towards increased physical activity.

Intervention 1: A supervised 12-week hospital-based moderate-to high-intensive physical training program equivalent to 40 metabolic equivalent (MET) / week. Includes various types of cardiovascular fitness activities, muscular strength, relaxation and massage.

Intervention 2: A non-supervised 12-week progressive pedometer program with a view to increasing participants physical activity to the minimum national recommendations of 150 minutes of moderate activity plus two times 20 minutes of strenuous activity / week.

Control: Control group participants are offered one of the two intervention after 12 weeks.

### **Intervention Type**

Other

### **Phase**

Not Applicable

### **Primary outcome measure**

Maximum oxygen uptake - VO<sub>2</sub>-peak measured baseline and at 6, 12 and 39 weeks

### **Secondary outcome measures**

1. Dual Energy X-ray Absorptiometry / DXA scan (Baseline and 12 weeks)
2. Muscular strength (baseline and at 6, 12 and 39 weeks)
3. Blood cholesterol (baseline, 12 and 39 weeks)
4. Blood pressure, pulse (baseline and 6, 12 and 39 weeks)
5. Body Mass index (baseline and 6, 12 and 39 weeks)
6. Performance status (baseline and 6, 12 and 39 weeks)
7. Self-reported physical activity, Quality of Life (EORTC QLQ C-30) (baseline and at 6, 12 and 39 weeks)
8. General Wellbeing (SF 36) (baseline and at 6, 12 and 39 weeks)
9. Anxiety and Depression (HADs) (baseline and at 6, 12 and 39 weeks)
10. Motivational readiness (baseline and at 6, 12 and 39 weeks)
11. Decisional balance (baseline and at 6, 12 and 39 weeks)
12. Exercise self-efficacy (baseline and at 6, 12 and 39 weeks)
13. Social support, (baseline and at 6, 12 and 39 weeks)
14. Labor market affiliation - Questions on matters relating to work for people who have a cancer and consist of 13 items (baseline and at 12 and 39 weeks)
15. Cardiovascular comorbidity
16. Disease free survival and recurrence (mainly 1 and 2 year follow-up data in the following RCT)

### **Overall study start date**

30/01/2012

### **Completion date**

30/01/2013

## **Eligibility**

### **Key inclusion criteria**

1. Patients diagnosed with breast cancer (stage I - III) or colon cancer (stage II and III) in adjuvant chemotherapy
2. WHO performance status of 0 or 1
3. Aged 18 + years who do not meet criteria for recommended physical activity levels of 150 min /week of moderate leisure time physical activity, and exercises at least 20 minutes of strenuous physical activity twice a week

### **Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

Feasibility study n=45

**Total final enrolment**

45

**Key exclusion criteria**

1. Patients with myocardial infarction within the past three months
2. Symptomatic heart failure
3. Angina pectoris
4. Abnormal pathological ECG

**Date of first enrolment**

30/01/2012

**Date of final enrolment**

30/01/2013

**Locations****Countries of recruitment**

Denmark

**Study participating centre**

Copenhagen University Hospital Rigshospitalet Department 9701

Copenhagen

Denmark

2100

**Sponsor information****Organisation**

Novo Nordic Foundation (Novo Nordisk Fonden) (Denmark)

**Sponsor details**

Tuborg Havnevej 19  
Hellerup Copenhagen  
Denmark  
2900  
+45 (0)3527 6600  
nnfond@novo.dk

**Sponsor type**

Research organisation

**Website**

<http://www.novonordiskfonden.dk/kontakt.asp>

**ROR**

<https://ror.org/04txyc737>

## Funder(s)

**Funder type**

Government

**Funder Name**

Novo Nordic Foundation (Denmark)

**Funder Name**

Danish Cancer Society (Denmark)

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>	protocol	04/11/2013	17/12/2020	Yes	No

<a href="#">Results article</a>	qualitative results	23/08/2017	17/12/2020	Yes	No
<a href="#">Results article</a>	results	23/10/2015	17/12/2020	Yes	No